Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis - Summary - MDSpire

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • By

  • Sharlene Dong

  • Rahul Banerjee

  • Adeel M. Khan

  • Mengru Wang

  • Xiaoliang Wang

  • Anosheh Afghahi

  • Aimaz Afrough

  • Murali Janakiram

  • Bo Wang

  • Andrew J. Cowan

  • Adam S. Sperling

  • Larry D. Anderson

  • S. Vincent Rajkumar

  • Gurbakhash Kaur

  • March 28, 2025

  • 0 min

Share

Objective:

To analyze real-world prescribing patterns and clinical outcomes of carfilzomib in patients with relapsed or refractory multiple myeloma (RRMM).

Key Findings:
  • Include specific data points or percentages to support findings.
Interpretation:

Emphasize specific future research directions.

Limitations:
  • Add brief explanations of how limitations may impact findings.
Conclusion:

Reiterate the importance of addressing research gaps.

Original Source(s)

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • by Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur

  • March 28, 2025

Related Content

Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence

Evaluating Hypoalbuminemia as a Prognostic Indicator in Monoclonal Gammopathy of Undetermined Significance (MGUS) within Its Biological Framework

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma